Prognostic significance of castrate testosterone levels for patients with intermediate and high risk prostate cancer

doi:10.5306/wjco.v10.i8.283

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 8

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7752)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-4) series.

Item

Count

PDF

432

WORD

240

HTML

4570

Figures (1-4)

285

Tables (1-4)

158

Sum=5685

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

682

Download

1385

Sum=2067

Aug 24, 2019 (publication date) through Apr 24, 2024

Times Cited of This Article

Times Cited (4)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Clin Oncol. Aug 24, 2019; 10(8): 283-292
Published online Aug 24, 2019. doi: 10.5306/wjco.v10.i8.283

Full Size Figure Download Figure

Figure 2 Five and 10 years biochemical relapse free survival rates when castrate testosterone level of < 50 ng/dL is used (P = 0. 006).

Citation: Ozyigit G, Hurmuz P, Yuce D, Akyol F. Prognostic significance of castrate testosterone levels for patients with intermediate and high risk prostate cancer. World J Clin Oncol 2019; 10(8): 283-292
URL: https://www.wjgnet.com/2218-4333/full/v10/i8/283.htm
DOI: https://dx.doi.org/10.5306/wjco.v10.i8.283